GlyxoVaxyn raises 25M SwFr to progress conjugate vaccine

Schlieren, Switzerland-based GlycoVaxyn, a pioneer in the development of innovative conjugated vaccines, has successfully closed a 25.0  million-Swiss franc ($21.3 million) series B financing. The round was  led by Edmond de Rothschild Investment Partners. Existing investors,  Index Ventures and Sofinnova Partners, expressed their commitment to the  future of the company through significant participation in this round.

GlycoVaxyn has developed a proprietary technology that allows the  engineering of a new type of conjugate vaccine, glycoconjugates. This  innovation will enable the firm to address significant unmet medical  needs in both industrialized and emerging countries.

The new funds will be used to advance the company's lead vaccine  candidate for intestinal infections, Shigellosis, which can cause a  major public health issue, into clinical development within the next 12  months. GlycoVaxyn also aims to reach key milestones in its  Staphylococcus aureus, Group B meningococcal and Group A Streptococcus  conjugate vaccine programs.